

# BLISS GVS PHARMA LTD.



July 31, 2020

To The Manager, Listing Department <b>National Stock Exchange of India Ltd.</b> Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Symbol: <b>BLISSGVS</b>	To The General Manager, Listing Department <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: <b>506197</b>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Sub: Annual Secretarial Compliance Report for the year ended March 31, 2020**

Dear Sir/Madam,

Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/27/2019 dated 8<sup>th</sup> February, 2019, please find enclosed herewith Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2020.

This is for your information and record.

Thanking You,

Yours Truly,  
For Bliss GVS Pharma Limited

Aditi Bhatt  
Company Secretary



**Regd. Office :** 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

**Factory :** Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

# **AVS & ASSOCIATES**

## **Company Secretaries**

**Regd. Office:** S-27, Haware Fantasia Business Park, Next to Inorbit Mall, Sector 30A, Vashi,  
Navi Mumbai -400703, Maharashtra, India

**Email:** [avsassociates16@gmail.com](mailto:avsassociates16@gmail.com)

**Tel:** 022-49785430 / 49785431 / 27810071

### **Secretarial Compliance Report of Bliss GVS Pharma Limited** **for the year ended March 31, 2020**

We, AVS & Associates have examined:

- a) All the documents and records made available to us and explanations provided by **Bliss GVS Pharma Limited ("the listed entity" or "the Company")**,
- b) the filings/submissions made by the listed entity to the stock exchanges i.e. BSE & NSE,
- c) Website of the listed entity,
- d) Any other document/ filing, as may be relevant, which has been relied upon to make this certification, for the year ended March 31, 2020 ("**Review Period**") in respect of compliance with the provisions of:
  - a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
  - b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/guidelines issued thereunder, have been examined, include:-

- a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (**Not applicable to the Company during the review period**);
- c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 (**Not applicable to the Company during the review period**);
- e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
- f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 (**Not applicable to the Company during the review period**);
- g) Securities and Exchange Board of India (Issue and Listing of Non Convertible and Redeemable Preference Shares) Regulations, 2013 (**Not applicable to the Company during the review period**);

h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

i) Securities and Exchange Board of India (Depositories and Participant) Regulations, 2018;

and circulars/guidelines issued thereunder applicable to the listed entity.

and based on the above examination, we hereby report that, during the Review Period:

a) The listed entity has complied with the provisions of the above Regulations and circulars/guidelines issued thereunder, except in respect of matters specified below:-

Sr. No	Compliance Requirement (Regulations/ circulars / guidelines including specific clause)	Deviations	Observations/ Remarks of the Practicing Company Secretary
1	Passing of Special Resolution for continuation of directorship of Non-Executive Director w.e.f. 1 <sup>st</sup> April, 2019, who has attained the age of seventy five years pursuant to Regulation 17(1A) of SEBI (LODR) 2015.	The Company has taken approval of shareholders as Special Resolution for continuation of directorship of Independent Director w.e.f. 27 <sup>th</sup> August, 2019 instead of 1 <sup>st</sup> April, 2019 who has attained the age of seventy five years.	Special Resolution passed by the shareholders for continuation of directorship of Mr. Subramanian Ramaswamy Vaidya as Independent Director of the Company w.e.f. 27 <sup>th</sup> August, 2019 instead of 1 <sup>st</sup> April, 2019 who has attained the age of seventy five years pursuant to regulation 17(1A) of SEBI (LODR) 2015.
2	Submission of Form-C for dealings in shares by promoter of the Company as required under Regulation 7(2) of SEBI (PIT), 2015.	In the absence of receipt of disclosures, the Company has submitted disclosures for dealings in shares by Mr. Mangesh Wagle suomoto after the review period.	Disclosures under Regulation 7(2) of SEBI (PIT), 2015 for dealings in shares by Mr. Mangesh Wagle, Promoter has not being received during the review period but was filed subsequently suomoto by the company after the review period. Further, as informed by the management, the said promoter is not associated with the company since year 2006.

b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/guidelines issued thereunder insofar as it appears from our examination of those records. However, we are not able to check and comment on structured digital database as required to be maintained under regulation 3(5) of SEBI (PIT), 2015 due to inability of our personal visit at office of the Company considering lockdown in the state due to COVID-19.

- c) The following are the details of actions taken against the listed entity/its promoters/directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/Regulations and circulars/ guidelines issued thereunder during the review period:

Sr. No.	Action taken by	Details of violation	Details of action taken E.g. fines, warning letter, debarment, etc.	Observations/ remarks of the Practicing Company Secretary, if any.
NIL				

- d) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No.	Observations of the Practicing Company Secretary in the previous reports	Observations made in the secretarial compliance report for the year ended 31.3.2019	Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the actions taken by the listed entity
Not Applicable				

Place: Kalyan, Thane  
Date: 31/07/2020

For AVS & Associates  
Company Secretaries




Vijay Yadav  
Partner  
Membership No: A39251  
CP No: 16806  
UDIN: A039251B000538651

Note: Due to lockdown in the state because of COVID-19, we were not able to personally visit at the office of the company for verification of documents physically and hence obtained most of the documents, details, information in electronic mode and taken necessary explanations, clarifications and representations either telephonically or electronically whenever required.